TC Biopharm (Holdings) Plc
TCBPY
$0.28
$0.000.00%
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -769.43% | -316.76% | -398.13% | 19.45% | 88.26% |
| Total Depreciation and Amortization | -18.19% | -22.08% | -24.57% | -24.30% | -25.96% |
| Total Amortization of Deferred Charges | -55.95% | -55.95% | -55.95% | -76.98% | -62.33% |
| Total Other Non-Cash Items | 127.42% | 61.51% | 26.14% | -5.10% | -4,572.94% |
| Change in Net Operating Assets | 93.95% | 104.67% | 108.32% | 59.13% | -53.25% |
| Cash from Operations | 28.00% | 21.96% | 29.39% | 21.37% | 3.05% |
| Capital Expenditure | 107.38% | 102.92% | 53.01% | -88.09% | -1,209.24% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -0.31% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 47.42% | 27.58% | 21.30% | 30.61% | 27.59% |
| Cash from Investing | 93.48% | 82.56% | 31.74% | -27.16% | -145.48% |
| Total Debt Issued | -- | -- | -- | -100.00% | -100.00% |
| Total Debt Repaid | 213.07% | 112.78% | 106.77% | 100.44% | 93.38% |
| Issuance of Common Stock | 297.59% | 41.88% | 53.96% | 12.72% | -34.95% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -93.39% | -94.71% | -81.38% | -63.23% | -37.68% |
| Cash from Financing | -10.05% | -63.47% | -54.37% | -53.22% | -51.75% |
| Foreign Exchange rate Adjustments | 115.73% | -90.75% | -96.57% | -108.24% | -116.50% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 76.89% | -339.85% | -168.11% | -178.86% | -167.15% |